Quadrant Capital Group’s Dianthus Therapeutics DNTH Stock Holding History

Quadrant Capital Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	2536
2021 Q4	$0	Buy	+4	New	+$402	﹤0.01%	2548

Other funds holding DNTH

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Quadrant Capital Group's DNTH Position: Q1 2022 in Review

Quadrant Capital Group sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 4 shares.

Quadrant Capital Group first reported a position in DNTH in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

Quadrant Capital Group reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
Quadrant Capital Group sold 4 Dianthus Therapeutics shares in Q1 2022.
Quadrant Capital Group first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 1 quarter.
Quadrant Capital Group's Dianthus Therapeutics position peaked at $0 in Q4 2021.
93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.